Kate O'COnnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kate O'COnnell has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Josephine Hegarty
Catherine McAuley School of Nursing and Midwifery University College Cork Cork Ireland
3 shared publications - Samantha J. Cushen
Clinical Nutrition and Oncology Research Group, School of Food and Nutritional Sciences, University College Cork, T12 K8AF Cork, Ireland
3 shared publications Andrea Davis
Department of Clinical Nutrition and Dietetics, Cork University Hospital, Cork, Ireland
2 shared publicationsAoife Lowery
HRB Clinical Research Facility, University of Galway, Galway, Ireland
2 shared publicationsBrendan Palmer
HRB Clinical Research Facility, School of Public Health, University College Cork, Cork, Ireland; School of Public Health, University College Cork, Cork, Ireland
2 shared publicationsDarren Dahly
HRB Clinical Research Facility, School of Public Health, University College Cork, Cork, Ireland; School of Public Health, University College Cork, Cork, Ireland
2 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by Elsevier in The Breast
- Vol. 86, 104740
A complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial
- 19 February 2026
- Published by Elsevier in The Breast
- Vol. 86, 104740
Open AccessA complex survivorship intervention utilizing electronic patient-reported outcomes in breast and gynecologic Cancer: the linking you to support and advice [LYSA] trial
- Open Access
- 7 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 77
A Dietitian Survivorship Clinic for Early-Stage Breast and Gynaecologic Cancer Survivors: A Dietetic Protocol for the Linking You to Support and Advice (LYSA) Randomised Controlled Trial
Background To align with the EU Beating Cancer Plan, feasible and innovative solutions that monitor specific needs of cancer survivors, improve quality of life and long-term disease-free survival need to be investigated. The Linking You to Support and Advice (LYSA) Trial was a multisite, randomized feasibility trial, co-designed with public and patient involvement. Eligible participants had early-stage hormone receptor (HR)-positive breast or gynaecologic cancer, completed primary curative treatment within 12 months and had internet access (NCT05035173). The 12-month intervention involved a dietitian and nurse-led clinic targeting symptom management. Detailed protocols targeted towards dietetic services and interventions are limited in this cohort. The dietetic component of the LYSA Trial aims to evaluate the impact of using electronic patient reported outcomes (ePROs) on diet quality and body composition in HR-positive breast and gynaecologic cancer survivors. Over 12 months, changes in dietary intake, nutritional risk, body weight, lean tissue mass, adipose tissue mass and muscle strength will be assessed. Methods Comprehensive anthropometric and nutritional assessments were conducted at baseline and 12 months for both study arms. These included body composition through bioelectrical impedance analysis and World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) diet quality score. Participants in the experimental arm completed ePROs every 2 months for one year, assessing malnutrition risk, physical activity and weight gain concerns. A trigger-initiated nutritional management pathway, delivered via a telehealth platform was developed for worsening or severe individualised symptoms. Conclusion This protocol outlines the implementation of a dietetic cancer survivorship clinic, within a randomised control trial. The use of ePROs and digital technologies offers viable and innovative solutions to monitor the nutrition-specific needs of cancer survivors. Findings will inform the development of future dietetic survivorship services. Trial registration ClinicalTrials.gov , NCT05035173 . Retrospectively registered on September 5, 2021. Registered on OSF: doi:10.17605/OSF.IO/JM7FX.
- 7 July 2025
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 8, 77
Open AccessA Dietitian Survivorship Clinic for Early-Stage Breast and Gynaecologic Cancer Survivors: A Dietetic Protocol for the Linking You to Support and Advice (LYSA) Randomised Controlled Trial
Background To align with the EU Beating Cancer Plan, feasible and innovative solutions that monitor specific needs of cancer survivors, improve quality of life and long-term disease-free survival need to be investigated. The Linking You to Support and Advice (LYSA) Trial was a multisite, randomized feasibility trial, co-designed with public and patient involvement. Eligible participants had early-stage hormone receptor (HR)-positive breast or gynaecologic cancer, completed primary curative treatment within 12 months and had internet access (NCT05035173). The 12-month intervention involved a dietitian and nurse-led clinic targeting symptom management. Detailed protocols targeted towards dietetic services and interventions are limited in this cohort. The dietetic component of the LYSA Trial aims to evaluate the impact of using electronic patient reported outcomes (ePROs) on diet quality and body composition in HR-positive breast and gynaecologic cancer survivors. Over 12 months, changes in dietary intake, nutritional risk, body weight, lean tissue mass, adipose tissue mass and muscle strength will be assessed. Methods Comprehensive anthropometric and nutritional assessments were conducted at baseline and 12 months for both study arms. These included body composition through bioelectrical impedance analysis and World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) diet quality score. Participants in the experimental arm completed ePROs every 2 months for one year, assessing malnutrition risk, physical activity and weight gain concerns. A trigger-initiated nutritional management pathway, delivered via a telehealth platform was developed for worsening or severe individualised symptoms. Conclusion This protocol outlines the implementation of a dietetic cancer survivorship clinic, within a randomised control trial. The use of ePROs and digital technologies offers viable and innovative solutions to monitor the nutrition-specific needs of cancer survivors. Findings will inform the development of future dietetic survivorship services. Trial registration ClinicalTrials.gov , NCT05035173 . Retrospectively registered on September 5, 2021. Registered on OSF: doi:10.17605/OSF.IO/JM7FX.
- Open Access
- 10 November 2022
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 8 (1) , 1-12
The Women’s Health Initiative cancer survivorship clinic incorporating electronic patient-reported outcomes: a study protocol for the Linking You to Support and Advice (LYSA) randomized controlled trial
Background: The improved survival rate for many cancers in high-income countries demands a coordinated multidisciplinary approach to survivorship care and service provision to ensure optimal patient outcomes and quality of life. This study assesses the feasibility of introducing a Women’s Health Initiative cancer survivorship clinic in Ireland. Methods: The trial comprises an intervention and control arm. Two hundred participants will be recruited. Key eligibility (1) women with early-stage hormone receptor-positive breast or gynecologic cancer (cervix or endometrial), within 12 months of completion of primary curative therapy, and (2) access to the Internet. The complex intervention comprises a nurse-led clinic targeting symptom management through a trigger alert system, utilizing electronic patient-reported outcome (ePRO) assessments at baseline, and 2, 4, 6, 8, 10, and 12 months. It also includes input from a dietitian monitoring diet and nutritional status. The control group will receive their usual care pathway standard of care and attend the cancer survivorship clinic and complete ePRO assessments at the start and end of the study. The primary endpoint (feasibility) includes the proportion of enrolled participants who complete baseline and follow-up ePRO surveys and partake in health professional consultations after ePRO data triggers. Secondary endpoints include changes in cancer-related symptom scores assessed by ePROs, health-related Quality of Life Questionnaire (QLQ) scores, Appraisal Self-Care Agency-R scores, and adjuvant endocrine therapy medication adherence. A process evaluation will capture the experiences of participation in the study, and the healthcare costs will be examined as part of the economic analysis. Ethical approval was granted in December 2020, with accrual commencing in March 2021. Discussion: This protocol describes the implementation of a parallel arm randomized controlled trial (RCT) which examines the feasibility of delivering a Cancer Survivorship Clinic. The ePRO is an innovative symptom monitoring system which detects the treatment-related effects and provides individualized support for cancer survivors. The findings will provide direction for the implementation of future survivorship care. Trial registration: ClinicalTrials.gov, NCT05035173. Retrospectively registered on September 5, 2021
- 10 November 2022
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 8 (1) , 1-12
Open AccessThe Women’s Health Initiative cancer survivorship clinic incorporating electronic patient-reported outcomes: a study protocol for the Linking You to Support and Advice (LYSA) randomized controlled trial
Background: The improved survival rate for many cancers in high-income countries demands a coordinated multidisciplinary approach to survivorship care and service provision to ensure optimal patient outcomes and quality of life. This study assesses the feasibility of introducing a Women’s Health Initiative cancer survivorship clinic in Ireland. Methods: The trial comprises an intervention and control arm. Two hundred participants will be recruited. Key eligibility (1) women with early-stage hormone receptor-positive breast or gynecologic cancer (cervix or endometrial), within 12 months of completion of primary curative therapy, and (2) access to the Internet. The complex intervention comprises a nurse-led clinic targeting symptom management through a trigger alert system, utilizing electronic patient-reported outcome (ePRO) assessments at baseline, and 2, 4, 6, 8, 10, and 12 months. It also includes input from a dietitian monitoring diet and nutritional status. The control group will receive their usual care pathway standard of care and attend the cancer survivorship clinic and complete ePRO assessments at the start and end of the study. The primary endpoint (feasibility) includes the proportion of enrolled participants who complete baseline and follow-up ePRO surveys and partake in health professional consultations after ePRO data triggers. Secondary endpoints include changes in cancer-related symptom scores assessed by ePROs, health-related Quality of Life Questionnaire (QLQ) scores, Appraisal Self-Care Agency-R scores, and adjuvant endocrine therapy medication adherence. A process evaluation will capture the experiences of participation in the study, and the healthcare costs will be examined as part of the economic analysis. Ethical approval was granted in December 2020, with accrual commencing in March 2021. Discussion: This protocol describes the implementation of a parallel arm randomized controlled trial (RCT) which examines the feasibility of delivering a Cancer Survivorship Clinic. The ePRO is an innovative symptom monitoring system which detects the treatment-related effects and provides individualized support for cancer survivors. The findings will provide direction for the implementation of future survivorship care. Trial registration: ClinicalTrials.gov, NCT05035173. Retrospectively registered on September 5, 2021
- Open Access
- 2 September 2021
- Published by Taylor & Francis in Global Public Health
- Vol. 17 (9) , 2206-2221
Understanding the financial burden of incomplete abortion: An analysis of the out-of-pocket expenditure on postabortion care in eight public-sector health care facilities in Dakar, Senegal
Timely access to treatment is essential for women when they experience abortion complications. Out-of-pocket (OOP) expenditure is a known barrier to health care access. In 2018, we assessed the financial burden of accessing postabortion care (PAC) borne by women in Dakar, Senegal, where studies estimate that half of poor women with complications obtain PAC. We interviewed 729 women following discharge from PAC. Women reported expenditures on transportation, admission, treatment, family planning, hospitalisation, complementary tests, prescriptions, other medicines and materials. We compare women’s OOP on PAC by expenditure category, type of treatment and facility type, and use multiple generalised linear regression analysis to explain variation in overall OOP and forecast it under alternate scenarios. The average OOP was USD $93.84. At health centres it was $65.47 and at hospitals it was $120.47. The average cost of PAC using dilation and curettage was $112.37, manual vacuum aspiration was $99.84, and misoprostol $61.80. Overall OOP on PAC amounts, on average, to 15% of the average monthly salary for women living in Dakar. Strategies that emphasise timely access to misoprostol for treating complications in primary care settings will address the contribution of OOP costs to Senegal’s appreciable unmet need for PAC among the poor.
- 2 September 2021
- Published by Taylor & Francis in Global Public Health
- Vol. 17 (9) , 2206-2221
Open AccessUnderstanding the financial burden of incomplete abortion: An analysis of the out-of-pocket expenditure on postabortion care in eight public-sector health care facilities in Dakar, Senegal
Timely access to treatment is essential for women when they experience abortion complications. Out-of-pocket (OOP) expenditure is a known barrier to health care access. In 2018, we assessed the financial burden of accessing postabortion care (PAC) borne by women in Dakar, Senegal, where studies estimate that half of poor women with complications obtain PAC. We interviewed 729 women following discharge from PAC. Women reported expenditures on transportation, admission, treatment, family planning, hospitalisation, complementary tests, prescriptions, other medicines and materials. We compare women’s OOP on PAC by expenditure category, type of treatment and facility type, and use multiple generalised linear regression analysis to explain variation in overall OOP and forecast it under alternate scenarios. The average OOP was USD $93.84. At health centres it was $65.47 and at hospitals it was $120.47. The average cost of PAC using dilation and curettage was $112.37, manual vacuum aspiration was $99.84, and misoprostol $61.80. Overall OOP on PAC amounts, on average, to 15% of the average monthly salary for women living in Dakar. Strategies that emphasise timely access to misoprostol for treating complications in primary care settings will address the contribution of OOP costs to Senegal’s appreciable unmet need for PAC among the poor.